​

ResMed (RMD) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

RMD Stock Forecast

ResMed (RMD) stock forecast, based on 34 Wall Street analysts, predicts a 12-month average price target of $296.00, with a high of $305.00 and a low of $280.00. This represents a 17.30% increase from the last price of $252.35.

$150 $190 $230 $270 $310 $350 High: $305 Avg: $296 Low: $280 Last Closed Price: $252.35

RMD Stock Rating

ResMed stock's rating consensus is Buy, based on 34 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 17 Buy (50.00%), 12 Hold (35.29%), 5 Sell (14.71%), and 0 Strong Sell (0.00%).

Buy
Total 34 0 5 12 17 Strong Sell Sell Hold Buy Strong Buy

RMD Price Target Upside V Benchmarks

TypeNameUpside
StockResMed17.30%
SectorHealthcare Stocks 15.45%
IndustryMedical Instruments & Supplies Stocks15.15%

Price Target Trends

1M3M12M
# Anlaysts-511
Avg Price Target-$297.60$278.45
Last Closing Price$252.35$252.35$252.35
Upside/Downside-17.93%10.34%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Dec, 253961-19
Nov, 253961-19
Oct, 252961-18
Sep, 253861-18
Aug, 253861-18
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Nov 03, 2025Robert W. Baird$300.00$246.8821.52%18.88%
Oct 31, 2025Brett FishbinKeyBanc$299.00$244.1222.48%18.49%
Oct 31, 2025David BaileyMorgan Stanley$305.00$252.2620.91%20.86%
Oct 21, 2025Morgan Stanley$304.00$271.4112.01%20.47%
Oct 13, 2025Wells Fargo$280.00$272.002.94%10.96%
May 20, 2025David BaileyMorgan Stanley$286.00$248.1415.26%13.33%
Apr 24, 2025Brett FishbinKeyBanc$274.00$232.6517.77%8.58%
Apr 16, 2025Anthony PetroneMizuho Securities$265.00$211.4925.30%5.01%
Mar 05, 2025Stifel Nicolaus$240.00$223.837.22%-4.89%
Jan 31, 2025Adam MaederPiper Sandler$260.00$236.1810.09%3.03%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Oct 31, 2025KeyBancOverweightOverweighthold
Oct 21, 2025Morgan StanleyOverweightOverweighthold
Sep 18, 2025CitigroupBuyBuyinitialise
May 20, 2025Morgan StanleyOverweightOverweighthold
Apr 24, 2025RBC CapitalSector PerformSector Performhold
Apr 24, 2025KeyBancOverweightOverweighthold
Mar 05, 2025CitigroupNeutralBuyupgrade
Jan 31, 2025RBC CapitalSector PerformSector Performhold
Jan 31, 2025UBSSector PerformBuyupgrade
Jan 31, 2025KeyBancOverweightOverweighthold

Financial Forecast

EPS Forecast

$0 $3 $6 $9 $12 $15 Jun 21 Jun 22 Jun 23 Jun 24 Jun 25 Jun 26 Jun 27 Jun 28 Jun 29
Jun 21Jun 22Jun 23Jun 24Jun 25Jun 26Jun 27Jun 28Jun 29
Reported$3.27$5.34$6.12$6.94$9.55----
Avg Forecast$5.30$5.71$6.50$7.73$9.41$10.38$11.34$12.14$13.55
High Forecast$5.51$5.94$6.64$7.79$9.56$11.06$12.05$12.40$13.84
Low Forecast$5.13$5.53$6.30$7.63$9.16$9.64$10.70$11.77$13.13
Surprise %-38.30%-6.48%-5.85%-10.22%1.49%----

Revenue Forecast

$3B $4B $5B $6B $7B $8B Jun 21 Jun 22 Jun 23 Jun 24 Jun 25 Jun 26 Jun 27 Jun 28 Jun 29
Jun 21Jun 22Jun 23Jun 24Jun 25Jun 26Jun 27Jun 28Jun 29
Reported$3.20B$3.58B$4.22B$4.69B$5.15B----
Avg Forecast$3.12B$3.58B$4.24B$4.68B$5.12B$5.50B$5.89B$6.31B$6.97B
High Forecast$3.22B$3.69B$4.31B$4.70B$5.16B$5.59B$5.90B$6.41B$7.08B
Low Forecast$3.04B$3.49B$4.14B$4.66B$5.09B$5.26B$5.88B$6.16B$6.80B
Surprise %2.48%0.04%-0.36%0.12%0.50%----

Net Income Forecast

$0 $500M $1B $2B $2B $3B Jun 21 Jun 22 Jun 23 Jun 24 Jun 25 Jun 26 Jun 27 Jun 28 Jun 29
Jun 21Jun 22Jun 23Jun 24Jun 25Jun 26Jun 27Jun 28Jun 29
Reported$474.50M$779.44M$897.56M$1.02B$1.40B----
Avg Forecast$559.05M$492.41M$959.76M$1.11B$1.38B$1.48B$1.62B$1.79B$2.00B
High Forecast$670.86M$621.54M$980.02M$1.34B$1.41B$1.63B$1.78B$1.83B$2.04B
Low Forecast$447.24M$363.28M$929.76M$890.31M$1.35B$1.42B$1.58B$1.74B$1.94B
Surprise %-15.12%58.29%-6.48%-8.26%1.40%----

RMD Forecast FAQ

Is ResMed stock a buy?

ResMed stock has a consensus rating of Buy, based on 34 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 17 Buy, 12 Hold, 5 Sell, and 0 Strong Sell, reflecting a consensus that ResMed is a favorable investment for most analysts.

What is ResMed's price target?

ResMed's price target, set by 34 Wall Street analysts, averages $296 over the next 12 months. The price target range spans from $280 at the low end to $305 at the high end, suggesting a potential 17.30% change from the previous closing price of $252.35.

How does ResMed stock forecast compare to its benchmarks?

ResMed's stock forecast shows a 17.30% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the medical instruments & supplies stocks industry (15.15%).

What is the breakdown of analyst ratings for ResMed over the past three months?

  • December 2025: 15.79% Strong Buy, 47.37% Buy, 31.58% Hold, 5.26% Sell, 0% Strong Sell.
  • November 2025: 15.79% Strong Buy, 47.37% Buy, 31.58% Hold, 5.26% Sell, 0% Strong Sell.
  • October 2025: 11.11% Strong Buy, 50.00% Buy, 33.33% Hold, 5.56% Sell, 0% Strong Sell.

What is ResMed’s EPS forecast?

ResMed's average annual EPS forecast for its fiscal year ending in June 2026 is $10.38, marking a 8.69% increase from the reported $9.55 in 2025. Estimates for the following years are $11.34 in 2027, $12.14 in 2028, and $13.55 in 2029.

What is ResMed’s revenue forecast?

ResMed's average annual revenue forecast for its fiscal year ending in June 2026 is $5.5B, reflecting a 6.78% increase from the reported $5.15B in 2025. The forecast for 2027 is $5.89B, followed by $6.31B for 2028, and $6.97B for 2029.

What is ResMed’s net income forecast?

ResMed's net income forecast for the fiscal year ending in June 2026 stands at $1.48B, representing an 5.41% increase from the reported $1.4B in 2025. Projections indicate $1.62B in 2027, $1.79B in 2028, and $2B in 2029.